PubRank

S J Cryz

Author PubWeight™ 119.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Isolation and characterization of Pseudomonas aeruginosa PAO mutant that produces altered elastase. J Bacteriol 1980 5.74
2 Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 1998 3.22
3 Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun 1982 2.76
4 Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect Immun 1984 2.39
5 Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988 2.09
6 Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992 1.94
7 Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 1993 1.93
8 Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development. J Clin Microbiol 1986 1.92
9 Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 1990 1.88
10 Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun 1983 1.79
11 Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 1995 1.73
12 Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000 1.67
13 Regulation of toxinogenesis in Corynebacterium diphtheriae: mutations in the bacterial genome that alter the effects of iron on toxin production. J Bacteriol 1983 1.60
14 Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun 1983 1.57
15 Genetic and biochemical evidence for a siderophore-dependent iron transport system in Corynebacterium diphtheriae. Infect Immun 1984 1.53
16 Isolation and characterization of a Pseudomonas aeruginosa mutant producing a nontoxic, immunologically crossreactive toxin A protein. Proc Natl Acad Sci U S A 1980 1.50
17 Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994 1.48
18 Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun 1983 1.45
19 Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines. Lancet 1990 1.41
20 Experimental Klebsiella pneumoniae burn wound sepsis: role of capsular polysaccharide. Infect Immun 1984 1.39
21 Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun 1984 1.38
22 Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999 1.38
23 Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992 1.35
24 Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 1987 1.33
25 Immunochemical studies of diphtherial toxin and related nontoxic mutant proteins. Infect Immun 1980 1.32
26 Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 1999 1.31
27 Progress in immunization against Klebsiella infections. Eur J Clin Microbiol 1983 1.22
28 Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis 1996 1.21
29 Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans. J Infect Dis 1986 1.19
30 Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide. Infect Immun 1984 1.14
31 Purification and vaccine potential of Klebsiella capsular polysaccharides. Infect Immun 1985 1.14
32 Production of alkaline protease by Pseudomonas aeruginosa. J Clin Microbiol 1980 1.12
33 Development of an enzyme-linked immunosorbent assay for studying Vibrio cholerae cell surface antigens. J Clin Microbiol 1982 1.12
34 Cell-associated hemagglutinin-deficient mutant of Vibrio cholerae. Infect Immun 1987 1.12
35 Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine. Infect Immun 1986 1.10
36 Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid. Infect Immun 1982 1.10
37 Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am J Respir Crit Care Med 1995 1.10
38 Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 1986 1.09
39 Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 1994 1.07
40 Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol 1993 1.06
41 Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun 1987 1.06
42 Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping. Infect Immun 1989 1.05
43 Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 1985 1.05
44 Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 1992 1.05
45 Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia. Infect Immun 1992 1.04
46 Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide. J Infect Dis 1984 1.03
47 Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991 1.02
48 Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 1994 1.00
49 Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997 0.99
50 Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia. Eur J Clin Microbiol Infect Dis 1993 0.99
51 Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans R Soc Trop Med Hyg 1995 0.97
52 Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies. Infect Immun 1981 0.96
53 Development of a rat model for respiratory infection with Bordetella pertussis. Infect Immun 1989 0.96
54 Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 2000 0.96
55 Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 1986 0.93
56 Optimization of growth and secretion of human monoclonal antibodies by hybridomas cultured in serum-free media. Hybridoma 1991 0.92
57 Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000 0.92
58 Human monoclonal antibodies specific for capsular polysaccharides of Klebsiella recognize clusters of multiple serotypes. J Immunol 1991 0.91
59 A murine monoclonal antibody against Klebsiella capsular polysaccharide is opsonic in vitro and protects against experimental Klebsiella pneumoniae infection. Microb Pathog 1988 0.90
60 Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. J Infect Dis 1992 0.90
61 Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol Microbiol 1993 0.89
62 Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J Infect Dis 1992 0.89
63 Activity of intravenous immune globulins against Klebsiella. J Lab Clin Med 1986 0.89
64 Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites. Infect Immun 1988 0.88
65 Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae. Mol Microbiol 1996 0.88
66 Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992 0.88
67 Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997 0.87
68 Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae. Infect Immun 1982 0.87
69 Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 1994 0.86
70 Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect Immun 1999 0.85
71 Escherichia coli and Klebsiella vaccines and immunotherapy. Infect Dis Clin North Am 1990 0.85
72 Construction and characterization of a potential live oral carrier-based vaccine against Vibrio cholerae O139. Infect Immun 1996 0.84
73 Cloning of the recA gene of Bordetella pertussis and characterization of its product. Biochimie 1991 0.83
74 Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle. Behring Inst Mitt 1997 0.83
75 Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients. Blood 1990 0.83
76 Post-marketing experience with live oral Ty21a vaccine. Lancet 1993 0.83
77 Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides. Infect Immun 1989 0.82
78 Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 2000 0.82
79 Humoral and cellular immune response in mice and dogs induced by a recombinant Echinococcus multilocularis antigen produced by a Salmonella typhimurium vaccine strain. Parasite Immunol 1990 0.82
80 Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A. APMIS 1994 0.81
81 Scale-up and optimization of culture conditions of a human heterohybridoma producing serotype-specific antibodies to Pseudomonas aeruginosa. Appl Microbiol Biotechnol 1992 0.81
82 Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides. Eur J Clin Microbiol 1985 0.81
83 Immunotherapy of sepsis: flawed concept or faulty implementation? Vaccine 1999 0.81
84 Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 1995 0.81
85 Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun 1993 0.80
86 Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis. J Infect Dis 1998 0.80
87 Local and systemic immune responses to combined vibrio cholerae CVD103-HgR and salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization. Vaccine 2000 0.80
88 New insights into the epidemiology, pathogenesis and therapy of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1985 0.79
89 Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 1996 0.79
90 Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults. Vaccine 1996 0.79
91 Toxoids of Pseudomonas aeruginosa toxin A: production by chemical and genetic means. Rev Infect Dis 1984 0.79
92 Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide. Infect Immun 1996 0.79
93 Qualitative analysis of antibody binding. An in vitro assay for the evaluation and development of vaccines. J Immunol Methods 1990 0.78
94 Protection of piglets against neonatal colibacillosis based on antitoxic immunity. Dev Biol Stand 1983 0.78
95 Further characterization of the Salmonella typhi Ty21a vaccine strain. J Infect Dis 1988 0.78
96 Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides. Dev Biol Stand 1990 0.78
97 Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR. Vaccine 1996 0.77
98 Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997 0.77
99 Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Hum Antibodies Hybridomas 1990 0.77
100 Detection of enterobacterial lipopolysaccharides and experimental endotoxemia by means of an immunolimulus assay using both serotype-specific and cross-reactive antibodies. J Infect Dis 1993 0.76
101 Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines. Dev Biol Stand 1983 0.76
102 Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect Immun 1996 0.75
103 Live oral cholera vaccine. Lancet 1997 0.75
104 Pseudomonas aeruginosa toxin-A-neutralising antibodies in normal human serum. Lancet 1988 0.75
105 Unusual persistence in healthy volunteers and ill patients of hyperimmune immunoglobulin directed against multiple Pseudomonas O-chain and Klebsiella serotypes after intravenous infusion. Vaccine 2001 0.75
106 Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients. Vaccine 1995 0.75
107 Exotoxin A from various Pseudomonas aeruginosa cultures: in vitro activity measured by enzyme-linked immunosorbent assay (ELISA). Acta Pathol Microbiol Immunol Scand B 1985 0.75
108 Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated p6olera CVD103-HgR and typhoid ty21a vaccines. J Infect Dis 1999 0.75
109 Anti-hepatitis A antibody titers after passive immunization with hepatitis A hyperimmune globulin. Southeast Asian J Trop Med Public Health 1995 0.75
110 The development of molecular vaccines against malaria sporozoites. Adv Exp Med Biol 1989 0.75
111 Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. Southeast Asian J Trop Med Public Health 1997 0.75
112 Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children. Vaccine 1999 0.75
113 Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies. FEMS Immunol Med Microbiol 1993 0.75
114 Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa. Res Immunol 1992 0.75
115 Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J Infect Dis 1994 0.75
116 Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995 0.75
117 Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J Acquir Immune Defic Syndr 1999 0.75
118 Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail. AIDS Res Hum Retroviruses 1994 0.75
119 A comparison of different methods for determining elastase activity of Pseudomonas aeruginosa strains from mink. Acta Pathol Microbiol Immunol Scand B 1986 0.75